MaaT Pharma SA announced the appointment of Gianfranco Pittari, M.D., Ph.D., as Chief Medical Officer. Dr. Pittari brings over 15 years of international experience in clinical research and drug development in hematology, oncology, and immunology. He will join the executive management team and oversee the clinical programs of the Company?s innovative microbiome-based drug candidates.

Dr. Pittari has extensive medical experience in drug development, particularly in oncology and hematology. His clinical work includes leading successful Phase I-III clinical trials at Celgene Corporation - Bristol Myers Squibb, where he was instrumental in the development of the first CAR T cell therapy for Multiple Myeloma (Abecma® - idecabtagene vicleucel), currently approved in both the US and the EU for use in earlier lines of treatment in patients with relapsed and refractory disease. Before joining MaaT Pharma, he served as Executive Medical Director at Autolus, a clinical-stage biopharmaceutical company developing next-generation, programmed T Cell therapies treating cancer and autoimmune disease.

He also held the position of Senior Consultant Hematology-BMT at the National Center for Cancer Care and Research in the State of Qatar, a leading international hub providing clinical care, where he treated patients with hematological conditions and took part in multiple academic initiatives. Dr. Pittari holds an M.D. degree from the University of Pavia, completed a Hematology fellowship at the University of Parma, and earned a Ph.D. in Immunology from Paris-Sud University. He has also conducted extensive academic research at both Gustave Roussy and Memorial Sloan-Kettering Cancer Center.